Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification

One promise of new translational safety biomarkers (TSBs) is their ability to demonstrate that toxicities in animal studies are monitorable at an early stage, such that human relevance of potential adverse effects of drugs can be safely and definitively evaluated in clinical trials. Another is that...

Full description

Saved in:
Bibliographic Details
Published inBiomarkers in medicine Vol. 5; no. 4; pp. 497 - 514
Main Authors Sistare, Frank D, DeGeorge, Joseph J
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.08.2011
Subjects
Animals
Biological markers
Biomarkers
Biomarkers, Pharmacological - metabolism
Clinical trials
Clinical Trials as Topic - economics
Clinical Trials as Topic - methods
Deoxyribonucleic acid
DNA
Drug Evaluation, Preclinical - economics
Drug Industry - economics
Drug-Related Side Effects and Adverse Reactions
Drugs
Gene expression
Government Regulation
Health aspects
Humans
Metabolites
NMR
Nuclear magnetic resonance
Patient safety
Pharmaceutical industry
Pharmaceutical Preparations - economics
Physiological aspects
Product development
Proteins
Rats
Studies
Toxicity
Toxicology
United States
Online AccessGet full text

Cover

More Information
Summary:One promise of new translational safety biomarkers (TSBs) is their ability to demonstrate that toxicities in animal studies are monitorable at an early stage, such that human relevance of potential adverse effects of drugs can be safely and definitively evaluated in clinical trials. Another is that they would provide an earlier, more definitive and deeper insight to patient prognosis compared with conventional biomarkers. Recent experience with regulatory authorities indicates that resource demands for new TSB qualifications under the current framework are daunting and the rate of their expansion will be slow, particularly in light of mounting financial pressures on the pharmaceutical industry. Sponsors face a dilemma over engaging in safety biomarker qualification consortia. While it is clear new TSBs could be considered catalysts to drug development and that patient health, business and scientific benefits, described here using examples, should outweigh qualification costs, concerns exist that early ambiguities in biomarker interpretations at the introduction of such new TSBs might hinder drug development.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1752-0363
1752-0371
DOI:10.2217/BMM.11.52